MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 201–300 of 623
Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00910-y · Cited by 41
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 41
Freeman, S. S., Sade-Feldman, M., Kim, J., Stewart, C., Gonye, A. L. K., Ravi, A., Arniella, M. B., Gushterova, I., LaSalle, T. J., Blaum, E. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100500 · Cited by 41
Tang, X., Sui, D., Liu, M., Zhang, H., Liu, M., Wang, S., Zhao, D., Sun, W., Liu, M., Luo, X., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119929 · Cited by 41
Chhibber, A., Huang, L., Zhang, H., Xu, J., Cristescu, R., Liu, X., Mehrotra, D. V., Shen, J., Shaw, P. M., Hellmann, M. D., et al. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.006 · Cited by 41
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 40
Baleeiro, R. B., Bouwens, C. J., Liu, P., Gioia, C. D., Chard, L. S., Nagano, A., Gangeswaran, R., Chelala, C., Kocher, H. M., Lemoine, N. R., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2080329 · Cited by 40
Lazaridou, M., Gonschorek, E., Massa, C., Friedrich, M., Handke, D., Mueller, A., Jasinski‐Bergner, S., Dummer, R., Koelblinger, P., & Seliger, B. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774323 · Cited by 40
Macy, A. M., Herrmann, L. M., Adams, A. C., & Hastings, K. T. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102330 · Cited by 40
Buetow, K. H., Meador, L. R., Menon, H., Lu, Y., Brill, J., Cui, H., Roe, D. J., DiCaudo, D. J., & Hastings, K. T. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900476 · Cited by 40
Prognostic and predictive biomarkers in melanoma
Maher, N. G., Vergara, I. A., Long, G. V., & Scolyer, R. A. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.004 · Cited by 39
Roles for the FCRL6 Immunoreceptor in Tumor Immunology
Davis, R. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575175 · Cited by 39
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 39
Lau, D., Khare, S., Stein, M. M., Jain, P., Gao, Y., BenTaieb, A., Rand, T., Salahudeen, A. A., & Khan, A. A. (2022) · Nature Communications · doi:10.1038/s41467-022-31769-4 · Cited by 38
Immunotherapy in melanoma: advances, pitfalls, and future perspectives
Sorino, C., Iezzi, S., Ciuffreda, L., & Falcone, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1403021 · Cited by 39
Amateur antigen‐presenting cells in the tumor microenvironment
Darragh, L. B., & Karam, S. D. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23354 · Cited by 38
Investigating T Cell Immunity in Cancer: Achievements and Prospects
Zeng, Z., Chew, H. Y., Cruz, J. L. G., Leggatt, G. R., & Wells, J. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062907 · Cited by 38
Chen, Y., Chang, W., Lin, E., Chen, Y., & Kuo, P. (2019) · Diagnostics · doi:10.3390/diagnostics9020059 · Cited by 38
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
Wang, H., Liu, G., Jin, X., Song, S., Chen, S., Zhou, P., Li, H., Liang, J., Li, B., Zhang, C., et al. (2022) · Journal of Cancer · doi:10.7150/jca.69375 · Cited by 38
Takashima, Y., Kawaguchi, A., Sato, R., Yoshida, K., Hayano, A., Homma, J., Fukai, J., Iwadate, Y., Kajiwara, K., Ishizawa, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46473-5 · Cited by 38
Yi, R., Hong, S., Zhang, Y., Lin, A., Ying, H., Zou, W., Wang, Q., Wei, T., Cheng, Q., Zhu, W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.757137 · Cited by 37
NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
Yoshihama, S., Cho, S., Yeung, J., Pan, X., Lizee, G. A., Konganti, K., Johnson, V. E., & Kobayashi, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82729-9 · Cited by 37
Peng, L., Zhou, L., Li, H., Zhang, X., Su, L., Wang, K., Yang, M., Ma, X., Zhang, D., Xiang, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114003 · Cited by 37
Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer
Lin, P., Lin, Y., Xu, C., Zhao, X., & Cui, L. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70403 · Cited by 36
Gorris, M. A. J., van der Woude, L. L., Kroeze, L. I., Bol, K. F., Verrijp, K. N., Amir, A. L., Meek, J., Textor, J. C., Figdor, C. G., & de Vries, I. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004329 · Cited by 36
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 36
LNK suppresses interferon signaling in melanoma
Ding, L., Sun, Q., Edwards, J. J., Fernández, L. T., Ran, X., Zhou, S., Scolyer, R. A., Wilmott, J. S., Thompson, J. F., Doan, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09711-y · Cited by 36
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 37
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0053 · Cited by 36
Kawase, K., Kawashima, S., Nagasaki, J., Inozume, T., Tanji, E., Kawazu, M., Hanazawa, T., & Togashi, Y. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0815 · Cited by 36
Zhang, H., Zhang, P., Lin, X., Tan, L., Wang, Y., Jia, X., Wang, K., Li, X., & Sun, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366096 · Cited by 36
Natural biomolecules and derivatives as anticancer immunomodulatory agents
Bernitsa, S., Dayan, R., Stephanou, A., Tzvetanova, I. D., & Patrikios, I. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070367 · Cited by 35
Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 34
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 34
Kamakura, D., Asano, R., Kawai, H., & Yasunaga, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02667-9 · Cited by 34
Langenbach, M., Giesler, S., Richtsfeld, S., Costa-Pereira, S., Rindlisbacher, L., Wertheimer, T., Braun, L. M., Andrieux, G., Duquesne, S., Pfeifer, D., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0898 · Cited by 34
James, J. L., Taylor, B. C., Axelrod, M. L., Sun, X., Guerin, L. N., Ericsson, P. I. G., Wang, Y., Sanchez, V. M., Fahey, C. C., Sanders, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007736 · Cited by 34
Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 34
Subramanian, M., Kabir, A. U., Barisas, D. A. G., Krchma, K., & Choi, K. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100896 · Cited by 34
Guercio, B. J., Iyer, G., Kidwai, W. Z., Lacouture, M. E., Ghafoor, S., Rossi, A. M., Assis, D. N., Chen, Y., BUSAM, K. J., Janjigian, Y. Y., et al. (2021) · Case Reports in Oncology · doi:10.1159/000514345 · Cited by 33
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
Nebhan, C. A., & Johnson, D. B. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1724539 · Cited by 32
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
Gu, S. S., Wang, X., Hu, X. S., Jiang, P., Li, Z., Traugh, N. C., Bu, X., Tang, Q., Wang, C., Zeng, Z., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02166-1 · Cited by 32
Applications of pyroptosis activators in tumor immunotherapy
Bao, X., Sun, M., Meng, L., Zhang, H., Yi, X., & Zhang, P. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101191 · Cited by 32
Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
Yi, W., Yan, D., Wang, D., & Li, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0009 · Cited by 32
Meier, M., Nuciforo, S., Coto‐Llerena, M., Gallon, J., Matter, M. S., Ercan, C., Vosbeck, J., Terracciano, L., Soysal, S. D., Boll, D. T., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00150-3 · Cited by 31
Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
Zhou, X., Qiu, S., Nie, L., Jin, D., Jin, K., Zheng, X., Yang, L., & Wei, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01429 · Cited by 31
Reduced MHC Class I and II Expression in HPV−Negative vs. HPV−Positive Cervical Cancers
Evans, A. M., Salnikov, M. Y., Tessier, T. M., & Mymryk, J. S. (2022) · Cells · doi:10.3390/cells11233911 · Cited by 32
Zhang, F., Yuan, D., Song, J., Chen, W., Wang, W., Zhu, G., Hu, B., Chen, X., & Zhu, J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107899 · Cited by 31
Iorgulescu, J. B., Ruthen, N. G., Ahn, R., Panagioti, E., Gokhale, P. C., Neagu, M. R., Speranza, M. C., Eschle, B. K., Soroko, K. M., Piranlioglu, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297932 · Cited by 30
Amrane, K., Meur, C. L., Besse, B., Hémon, P., Noach, P., Pradier, O., Berthou, C., Abgral, R., & Uguen, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285895 · Cited by 30
Miao, J., Li, J., Xin, J., Tu, J.-J., Ge, M., Qi, J., Zhou, X., Zhu, Y., Yang, C., & Lin, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-63418-x · Cited by 29
Liao, T., Chen, Y.-H., Li, Z.-Y., Hsiao, A.-C., Huang, Y.-L., Hao, R.-X., Tai, S., Chu, P., Shih, J.-W., Kung, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0622 · Cited by 29
Ameliorative Effects of Gut Microbial Metabolite Urolithin A on Pancreatic Diseases
Li, K., Xiao, Y., Bian, J., Han, L., He, C., El-Omar, E. M., Gong, L., & Wang, M. (2022) · Nutrients · doi:10.3390/nu14122549 · Cited by 29
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 30
Halle, M. K., Sødal, M., Forsse, D., Engerud, H., Woie, K., Lura, N. G., Wagner-Larsen, K. S., Trovik, J., Bertelsen, B. I., Haldorsen, I. S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01305-0 · Cited by 28
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I
Sun, X., Watanabe, T., Oda, Y., Shen, W., Ahmad, A. M., Ouda, R., de Figueiredo, P., Kitamura, H., Tanaka, S., & Kobayashi, K. S. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310821121 · Cited by 28
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
Tabasum, S., Thapa, D., Giobbie‐Hurder, A., Weirather, J. L., Campisi, M., Schol, P. J., Li, X., Li, J., Yoon, C. H., Manos, M. P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0171 · Cited by 28
Self-citationThe immune escape mechanism of nasopharyngeal carcinoma
Li, X., Guo, Y., Xiao, M., & Zhang, W. (2023) · The FASEB Journal · doi:10.1096/fj.202201628rr · Cited by 28
The multifaceted roles of CD4+ T cells and MHC class II in cancer surveillance
Bawden, E., & Gebhardt, T. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102345 · Cited by 27
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
Scott, S. C., Shao, X. M., Niknafs, N., Balan, A., Pereira, G., Marrone, K. A., Lam, V. K. L., Murray, J. C., Feliciano, J. L., Levy, B. P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.945798 · Cited by 27
CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
Jakobsen, M. K., & Gjerstorff, M. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01568 · Cited by 27
Felce, S. L., Anderson, A. P., Maguire, S., Gascoyne, D. M., Armstrong, R. N., Wong, K. K., Li, D., & Banham, A. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00448 · Cited by 27
Wei, Y., Ou, T., Lu, Y., Wu, G., Long, Y., Pan, X., & Yao, D. (2020) · PeerJ · doi:10.7717/peerj.10414 · Cited by 26
Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells
Zhao, M., Sun, Y., Jiang, X., Liu, L., Liu, L., & Sun, L. (2019) · Immunologic Research · doi:10.1007/s12026-019-09111-w · Cited by 26
Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
Li, T., Wang, X., Qin, S., Chen, B., Yi, M., & Zhou, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114712 · Cited by 26
Tundo, G. R., Sbardella, D., Oddone, F., Kudriaeva, A. A., Lacal, P. M., Belogurov, A. A., Graziani, G., & Marini, S. (2021) · Cancers · doi:10.3390/cancers13194852 · Cited by 26
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 26
Giri, S., Lamichhane, G., Pandey, J., Khadayat, R., Sindhu, K. C., Devkota, H. P., & Khadka, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072923 · Cited by 26
Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
Cerella, C., Dicato, M. A., & Diederich, M. F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106914 · Cited by 25
Gadeyne, L., Herck, Y. V., Milli, G., Atak, Z. K., Bolognesi, M. M., Wouters, J., Marcelis, L., Minia, A., Pliaka, V., Roznac, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.636057 · Cited by 25
MDM2 inhibitors in cancer immunotherapy: Current status and perspective
Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 25
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
Connor, A. E., LYONS, P., Kilgallon, A., Simpson, J. C., Perry, A. S., & Lysaght, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38888 · Cited by 25
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer
Dóra, D., Rivard, C. J., Yu, H., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., Gerdán, C., Dinya, E., Höetzenecker, K., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03270-w · Cited by 25
Lynce, F. C., Stevens, L. E., Li, Z., Brock, J. E., Gulvady, A. C., Huang, Y., Nakhlis, F., Patel, A., Force, J. M., Haddad, T. C., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01774-0 · Cited by 25
Porter, R. L., Sun, S., Flores, M. N., Berzolla, E., You, E., Phillips, I. E., KC, N., Desai, N., Tai, E. C., Szabolcs, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155931 · Cited by 24
“Given that lack of MHC-I expression is a common mechanism of resistance to immune checkpoint blockade (42–44), these findings raise the possibility that, in an in vivo setting, SAT repeat RNA modulation could synergize with immune checkpoint blockade by resensitizing cells to anti–PD-1 agents…”
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression
Zeng, Z., Gu, S. S., Ouardaoui, N., Tymm, C. C., Yang, L., Wong, C. J., Li, D., Zhang, W., Wang, X., Weirather, J. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0227 · Cited by 24
Self-citationBarroux, M., Househam, J., Lakatos, E., Ronel, T., Baker, A., Salié, H., Mossner, M., Smith, K., Kimberley, C., Nowinski, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00955-w · Cited by 24
Immunotherapy and Pancreatic Cancer: A Lost Challenge?
Laface, C., Memeo, R., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., Santis, P. D., et al. (2023) · Life · doi:10.3390/life13071482 · Cited by 24
Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 24
Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
Ran, X., Ding, L., Sun, Q.-Y., Yang, H. H., Said, J. W., Lao, Z., Madan, V., Dakle, P., Xiao, J.-F., Loh, X.-Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-21-3052 · Cited by 24
Ambler, R., Edmunds, G. L., Tan, S. L., Cirillo, S., Pernes, J. I., Ruan, X., Huete‐Carrasco, J., Wong, C. C. W., Lu, J., Ward, J., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aau4518 · Cited by 24
Flores-Martín, J. F., Perea, F., Ruíz, M. E., Carretero, F., Rodríguez, T., Villamediana, M., Ruiz‐Cabello, F., Garrido, F., Cozar-Olmo, J. M., & Aptsiauri, N. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07371-2 · Cited by 24
Yiu, S. P. T., Chang, Y., Yeo, Y. Y., Qiu, H., Wu, W., Michel, H. A., Jin, X., Huang, R., Kure, S., Parmelee, L. K., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0775 · Cited by 24
Self-citationLiang, Y., Zheng, Y., Zeng, Y., Hu, C., Si, Y., Fan, X., & Chen, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691608 · Cited by 23
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Rizk, E. M., Seffens, A., Trager, M. H., Moore, M. R., Geskin, L. J., Gartrell, R. D., Wong, W., & Saenger, Y. M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00475-1 · Cited by 23
Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y. H., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04079-6 · Cited by 23
Ferrarini, I., Rigo, A., Visco, C., Krampera, M., & Vinante, F. (2020) · Cancers · doi:10.3390/cancers12123757 · Cited by 23
The therapeutic potential of targeting minimal residual disease in melanoma
Patel, R. P., Somasundram, P. M., Smith, L. K., Sheppard, K. E., & McArthur, G. A. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1197 · Cited by 23
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
Iafolla, M. A. J., Yang, C., Chandran, V., Pintilie, M., Li, Q., Bedard, P. L., Hansen, A. R., Lheureux, S., Spreafico, A., Razak, A. A., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa115 · Cited by 23
Immunological and clinical implications of immune checkpoint blockade in human cancer
Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 22
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
Cruz‐Bermúdez, A., Briviesca, R. L., Casarrubios, M., Sierra‐Rodero, B., & Provencio, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040361 · Cited by 22
Chen, S., Huang, M., Zhang, L., Huang, Q., Wang, Y., & Yang, L. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.12.001 · Cited by 22
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Draghi, A., Presti, M., Jensen, A. W. P., Chamberlain, C. A., Albieri, B., Rasmussen, A.-C. K., Andersen, M. H., Crowther, M. D., Svane, I. M., & Donia, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3853 · Cited by 22
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 21
Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota
Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 21
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 22
Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice
Lin, W., Singh, V. J., Springer, R., Choonoo, G., Gupta, N., Patel, A. K., Frleta, D., Zhong, J., Owczarek, T. B., Decker, C. E., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04812-3 · Cited by 21
Decoding melanoma’s cellular mosaic to unlock immunotherapy potential
Poźniak, J., & Marine, J. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.01.009 · Cited by 21
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.